Novartis tops list of EU products under "additional monitoring"
This article was originally published in Scrip
Executive Summary
119 medicines are now on the EU's list of products that are subject to additional monitoring because they are new to the market or lack comprehensive data. Novartis has ten products on the list, followed by GlaxoSmithKline and Pfizer with eight each.